bioAffinity Technologies wins Japan patent allowance for CyPath Lung AI algorithm
Bitget2026/10/08 12:02bioAffinity Technologies received a notice of allowance from Japan’s patent office for an AI-driven method supporting its CyPath Lung cancer-risk prediction test. The filing covers early-stage lung cancer detection in sputum using automated flow cytometry with machine learning. The company expects the Japanese patent to be issued following payment of the required fee. The portfolio includes 22 granted patents worldwide, with 36 applications pending. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261008743266) on October 08, 2026, and is solely responsible for the information contained therein.
- bioAffinity Technologies received a notice of allowance from Japan’s patent office for an AI-driven method supporting its CyPath Lung cancer-risk prediction test.
- The filing covers early-stage lung cancer detection in sputum using automated flow cytometry with machine learning.
- The company expects the Japanese patent to be issued following payment of the required fee.
- The portfolio includes 22 granted patents worldwide, with 36 applications pending.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
